New drug shows promise for fatty liver disease in Mid-Stage trial
Disease control
Completed
This study tested a new medicine called BIO89-100 in 222 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease with moderate to severe scarring. The goal was to see if the drug could reverse liver inflammation and damage without making scarring worse. Par…
Phase: PHASE2 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated May 17, 2026 11:38 UTC